Included under the umbrella of University Surgical Cluster, some key research areas and strengths are the generation of minimal invasive endoscopic tools and related intellectual properties. We manufacture biosensors, flow sensors, less invasive surgical retractors and scopes. We also develop methodology to make heart and vascular surgery, more efficient and safer. In the colorectal field, we strive to improve the outcome in colorectal diseases by promoting minimal invasive surgical routes, targeting benign, anorectal disease as well as colorectal cancer. Colorectal cancer, pelvic floor disorders are further priorities, moreover, we use stem cells to address gastric cancer and discover biomarkers for locally advanced gastric cancer. We use Genomic- guided chemotherapy for gastric cancer patients who are at good risks and to address diabetes mellitus and obesity, we explore new Endoluminal Device for Duodenal exclusion for better control in the treatment of Type II diabetes and obesity In Plastic, Reconstructive & Aesthetic Surgery, we pursue scaffold technologies, adult stem cells for tissue regeneration as well as the usage of bio-imaging to better understand pathology & patho-physiology e.g. in facial trauma.
All surgical developments have to aim at reducing patient burden, pain and surgical trauma, to distribute high standards of care to wide masses of the population in the region and the world. Without research and investment in research projects, without research infrastructure and academic commitment, medicine and surgery stagnate. Progress is eliminated. However, diseases spread and change within evolving megatrends, as countries become more industrialized, lifestyle changes and people become older. New pandemics emerge. Without research and innovative surgical therapies many organs, organ systems, human lives cannot be salvaged. It is our vocation, in alignment with the most primary principles of health care, to lead the way to the future with research, teaching and innovation, and hopefully turn scientific concepts of today to useful therapies tomorrow.
The Wang Lab
A multidisciplinary team working on translational research in cardio-metabolic diseases: to discover pathogenic mechanisms, to identify novel therapeutic targets, and to create viable nanomedicines for targeted therapy, with a focus on the heart, the liver, and the gut.
More
Our team has been working on cardio-metabolic diseases, cardiac immunology, extracellular vesicles and nanomedicine. Our laboratory is working with various established pre-clinical animal models of human disease, including myocardial infarction, ischemia reperfusion injury, pressure overload, diet-induced heart failure), atherosclerosis and non-alcoholic fatty liver disease. The newly established NANONASH research program aims to tap unto brilliant and young scientists to develop new and effective nanomedicine-based therapies for the treatment of fatty liver disease. Our group also works on new nanomaterials and drug delivery systems (carrying small molecules, nucleic acids, RNAs etc) for translational research in cardiovascular disease, fatty liver disease and gut related disease. Our nanomedicine laboratory, the Centre for NanoMedicine, provides state-of-the-art technology to enable such research and expand the applications of nanomedicine for unmet clinical needs.
BICEPS Laboratory
Developing targeted Magnetic Mitohormesis strategies to improve human health, longevity and physical performance.
More
Wound Healing and Stem Cell Research Lab
Research and development of novel and affordable biological products for better treatment of non-healing wounds as resulted of aged related diseases
MOre